Current advances in digital cognitive assessment for preclinical Alzheimer's disease
| Autor: | Kathryn V. Papp, Michael Schöll, David Berron, Jason Hassenstab, Fredrik Öhman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
cognition
Coronavirus disease 2019 (COVID-19) Computer science preclinical Alzheimer's disease Disease Review Article smartphone‐based assessment computerized assessment Data Protection Act 1998 ddc:610 RC346-429 clinical trials business.industry RC952-954.6 Usability Cognition clinical assessment digital cognitive biomarkers Data science Clinical trial Psychiatry and Mental health Geriatrics Data quality Cognitive & Behavioral Assessment Neurology (clinical) Cognitive Assessment System Neurology. Diseases of the nervous system business home‐based assessment |
| Zdroj: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 13, Iss 1, Pp n/a-n/a (2021) Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring Alzheimer's & dementia / Diagnosis, assessment & disease monitoring 13(1), e12217 (2021). doi:10.1002/dad2.12217 |
| ISSN: | 2352-8729 |
| Popis: | There is a pressing need to capture and track subtle cognitive change at the preclinical stage of Alzheimer's disease (AD) rapidly, cost‐effectively, and with high sensitivity. Concurrently, the landscape of digital cognitive assessment is rapidly evolving as technology advances, older adult tech‐adoption increases, and external events (i.e., COVID‐19) necessitate remote digital assessment. Here, we provide a snapshot review of the current state of digital cognitive assessment for preclinical AD including different device platforms/assessment approaches, levels of validation, and implementation challenges. We focus on articles, grants, and recent conference proceedings specifically querying the relationship between digital cognitive assessments and established biomarkers for preclinical AD (e.g., amyloid beta and tau) in clinically normal (CN) individuals. Several digital assessments were identified across platforms (e.g., digital pens, smartphones). Digital assessments varied by intended setting (e.g., remote vs. in‐clinic), level of supervision (e.g., self vs. supervised), and device origin (personal vs. study‐provided). At least 11 publications characterize digital cognitive assessment against AD biomarkers among CN. First available data demonstrate promising validity of this approach against both conventional assessment methods (moderate to large effect sizes) and relevant biomarkers (predominantly weak to moderate effect sizes). We discuss levels of validation and issues relating to usability, data quality, data protection, and attrition. While still in its infancy, digital cognitive assessment, especially when administered remotely, will undoubtedly play a major future role in screening for and tracking preclinical AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text